Fabtech Technologies Ltd Q2 FY2026 Concall Summary

Key Takeaways

• A lumpy quarter, not a broken story: EBITDA margin swung from 8% to 25% QoQ, but management insists the project-based model makes quarterly numbers meaningless and the yearly trajectory is intact.
• The order book is the anchor: At ₹904.42 crore, it provides clear visibility for sustained revenue momentum, with 7–9% incremental growth per quarter in conversions.
• Management refuses to be pinned down: On every request for EBITDA guidance, medium-term growth forecasts, or a 3–5 year vision with a number, the answer was a version of “we will not overcommit and underachieve.”
• MENA is the structural bet: Saudi Arabia’s Vision 2030/2040 localization drive and a broader emerging-market push toward medicinal independence are creating a multi-year tailwind for turnkey pharma facilities.
• What to watch next quarter: Whether the 20–25% sustained YoY revenue growth target holds, if margins stay in the “~12%” range management pointed to, and any concrete detail on the KP Group sustainable-energy MOU.

The Lumpy Business Model

• Project cycles drive everything: Each project runs 18 to 24 months from concept to completion, and quarterly results swing as new projects enter and existing ones move through stages; management operates on yearly guidance only.
• Current project book status: Of the 20 projects worth INR137 crores, completion ranges from 30% to 80%, averaging 65%, so a meaningful portion of revenue is still to be recognized.
• Capacity is not the bottleneck: The business is not capital-intensive; the same team can handle double the revenue because execution relies on design and project-management capability, not fixed assets.
• Client readiness dictates pace: Clients must first complete market mapping and disease profiling before a facility project can begin, which introduces lumpiness Fabtech cannot control.

Anavkar: "Sir, usually our industry is considered a lumpy business. Quarter-to-quarter does not work exactly. So I will not be able to tell you how Q3 and Q4 will go. But we sustain yearly."

Order Book & Revenue Visibility

• ₹904.42 crore order book: Management cites this as clear visibility for sustained revenue momentum in coming quarters, with order conversions growing 7–9% incrementally each quarter.
• 20–25% sustained YoY growth target: This is the only growth figure management volunteered, framed as a sustained annual rate rather than a quarterly promise.
• Execution timeline is long-dated: All projects have a total execution period of 18 to 24 months, so the order book converts to revenue over multiple quarters.
• Peak execution capacity undisclosed: Management called the current pipeline “quite healthy” but declined to quantify peak execution capacity, and would not say what percentage of the ₹904 crore book will be realized this year.

Margins: The 8% to 25% Swing

• Structural drivers, not one-offs: Management attributes the margin jump to structural efficiencies driven by purchase teams, sales teams, and high-margin capex projects currently being concluded.
• Yearly margin anchor is ~12%: When pressed for a sustainable range for financial modeling, management pointed to “the similar range” of ~12% with certain sustainable growth over last year’s margins.
• Sustenance, not quarterly precision: Management’s focus is on ensuring margins sustain and outperform each year; they explicitly declined to put a number on forward EBITDA, saying they would not risk overcommitting and underachieving.
• Project mix determines quarterly margin: Because projects span 18–24 months and differ in profitability, quarter-to-quarter margin changes are a function of which projects are concluding and which are ramping, not a signal of structural shift.

Anavkar: "Our focus is to ensure sustenance."

MENA & the Localization Tailwind

• Medicinal independence is the macro driver: Emerging-market governments are pushing to localize not just finished formulations but also API production, raw materials, and secondary packing; this creates demand for the full turnkey facilities Fabtech builds.
• Saudi Arabia is the anchor: Vision 2030 and 2040 make localization a national priority, and Fabtech has a strong on-ground team evaluating projects by annual conversion potential.
• Regulatory compliance is a moat: All these emerging markets target compliance with USFDA, EU GMP, Saudi FDA, and other major regulators; Fabtech’s 30-year in-house design-and-build capability across process, air, and water systems makes it a preferred partner as clients expand from generic facilities to more potent drugs.
• Duration of the opportunity is open-ended: Management declined to estimate how long the MENA cycle will run, but the structural nature of the localization push suggests a multi-year horizon.

Anavkar: "If I must say specifically Saudi Arabia, they are in the vision 2030 and 2040, where localization is key for them. How long will this go on for? I would not be able to comment, but our team on ground, a very strong team, evaluates projects on the basis of conversions per year."

Strategic Focus & Boundaries

• Pharma, healthcare, biotech only: Management stated explicitly that the opportunity in these markets is large enough that they are not focused on non-pharma segments; the criticality of pharma manufacturing is the differentiator.
• KP Group MOU for sustainable energy: The partnership aims to broaden services, offer sustainable offerings within current projects, and increase the product profile by adding sustainable solutions for existing and new clients; no financial details were disclosed.
• 22-country footprint: Fabtech delivers start-to-end turnkey solutions across process, air, and water systems for pharmaceutical and biotech manufacturing globally.
• Working capital has room to improve: Management is working to reduce receivable cycles and improve collection procedures tied to timely project completions; some improvement is expected but not a dramatic change.

Anavkar: "Currently, our appetite is focused on pharmaceutical, healthcare and biotech markets because the opportunity is huge here, not focused on the non-pharma segment because the criticality in pharma is what we're focused on."

What Management Would Not Answer

• No EBITDA guidance, ever: Management declined to provide a range for one year, two years, or the medium term, calling it a risk of overcommitting and underachieving.
• No medium-term growth forecast: Requests for 2–3 year top-line and EBITDA growth forecasts were met with a reference to the growing order book and no numbers.
• No quarterly outlook: Management refused to characterize how Q3 and Q4 normally behave, reiterating that the business is lumpy and quarter-to-quarter does not work.
• No minimum growth floor: When asked if the company can grow at least 15% or 20%, management did not provide a figure.
• No margin guidance on the order book: Management declined to estimate EBITDA margins on the ₹960 crore order book, saying assumptions on open orders can be wrong until designs are complete.
• No 3–5 year vision with a number: Management said initiatives will be published in leading newspapers “time to time” but gave no timeline or concrete target.

Anavkar: "I would say we are forward looking, we are focusing on ensuring that these margins sustain and grow. Specifically, putting a number to it, we would not want to be in a situation where we overcommit it and underachieve, but we are focused on growth."

Guidance & Commitments

Key Metrics